Despite this, none of them contain type I IFN (e.g., IFN-α or IFN-β), although its substantial role has been highlighted in several ADs, including SLE, where multiple approved or developing therapies are designed to block the type I IFN-inducible pathway of inflammation. Here, IFNB1 is linked to systemic lupus erythematosus.